Germline Warfare
By Ralph Brave,
The Nation
| 04. 07. 2003
A most remarkable event occurred in the weeks preceding the
June 2000 announcement of the completion of the first draft
of the human genome DNA code: One of the leaders of the genome
project publicly called for strict limits on what the scientific
community should be permitted to do with the human genetic blueprint
now in hand.
At a conference at MIT, Dr. Eric Lander, leader of the team
that decoded the largest portion of the genome, called the conference
to attention with this surprisingly stark suggestion:
Already, there are well-meaning discussions about improving
the human DNA. I find this somewhat hubristic myself. [The human
genome] has been 3.5 billion years in the making. We've been
able to read it for the last, oh, I don't know, year or so.
And we suddenly think we could write the story better? It's
very amusing.
There is the prospect that by changing things we might put
off aging, prevent cancer, improve memory. I find it a very
difficult question. For my own part, I would put an absolute
ban in place on...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...